Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
We did a randomised, open-label, phase 3 trial at 17 cancer centres in France. Eligible patients were aged 18–70 years and had colorectal cancer with...
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials
Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer. 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fract...
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. The HYPO-RT-PC trial was d...
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
German Hodgkin Study Group HD17 trial investigated whether radiotherapy could be omitted without loss of efficacy in patients with early-stage unfavou...
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
PALLAS is an ongoing multicentre, open-label, randomized, phase 3 study that enrolled patients at 406 cancer centers in 21 countries. 3-year invasive...
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC) The most common...
Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study
In-depth analyses of the global demand for cancer surgery and optimal workforce requirements are needed to plan service providers. The number of cance...